Vicuron Pharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: King of Prussia PA United States (1995)
Status: Acquired by Pfizer (2005)

Organization Overview

First Clinical Trial
2001
NCT00057369
First Marketed Drug
2006
anidulafungin (eraxis)
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

VICURON | VICURON HOLDINGS

Active Ingredients

Marketed Drugs (1)

anidulafungin (eraxis) (2006)

Drugs in Phase 3 Trials (2)

anidulafungin (eraxis) (5 trials)

fluconazole (diflucan) (1 trial)

Drugs in Phase 2 Trials (1)

dalbavancin (dalvance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aspergillosis (Phase 3)

Bacteremia (Phase 2)

Candidemia (Phase 3)

Candidiasis (Phase 3)

Candidiasis, Invasive (Phase 3)

Neutropenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3